Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 24; no. 7; pp. 468 - 477
• Main Authors: Kastritis, Efstathios, Ntanasis-Stathopoulos, Ioannis, Theodorakakou, Foteini, Migkou, Magdalini, Roussou, Maria, Malandrakis, Panagiotis, Kanellias, Nikolaos, Eleutherakis-Papaiakovou, Evangelos, Fotiou, Despina, Spiliopoulou, Vassiliki, Gavriatopoulou, Maria, Patel, Sachin, Majer, Istvan, Boukis, Christos, Fetani, Andriani, Dimopoulos, Meletios A., Terpos, Evangelos
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2024
• Subjects: Aged; Aged, 80 and over; Databases, Factual; Drug Resistance, Neoplasm; Female; Greece; Humans; Lenalidomide - therapeutic use; Lenalidomide-refractory; Male; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; Real-world; Retrospective Studies; Second-line therapy; Survival; Treatment Outcome; Treatment strategy; Greece; Treatment strategy; Lenalidomide-refractory; Survival; Real-world; Second-line therapy

•Survival is poor in patients refractory to first-line lenalidomide (Len).•Limited real-world data on treatment patterns and outcomes exist in these patients.•Len-refractory patients commonly received proteasome-inhibitor and triplet regimens.•Survival times of optimal regimens were poor versus non-...